Judith A Smith

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines
    Marisa A Navo
    Division of Pharmacy, The University of Texas, M D Anderson Cancer Center, Houston, TX 77230, USA
    Cancer Chemother Pharmacol 62:483-9. 2008
  2. ncbi request reprint Use of complementary and alternative medications among patients in an obstetrics and gynecology clinic
    Judith A Smith
    Division of Surgery, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Reprod Med 57:390-6. 2012
  3. ncbi request reprint Implementation of cytokines to optimize cancer treatment outcomes
    Judith A Smith
    Department of Gynecologic Oncology, Division of Surgery, The University of Texas M D Anderson Cancer Center, PO Box 301439 Unit 1362, Houston, TX 77230 1439, USA
    J Support Oncol 5:89-91. 2007
  4. ncbi request reprint An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines
    Judith A Smith
    Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Gynecol Oncol 92:314-9. 2004
  5. ncbi request reprint Evaluation of patient chemotherapy education in a gynecology oncology center
    Judith A Smith
    Division of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Support Care Cancer 12:577-83. 2004
  6. ncbi request reprint Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines
    Judith A Smith
    Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Gynecol Oncol 103:518-22. 2006
  7. ncbi request reprint An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines
    Judith A Smith
    Department of Gynecologic Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Gynecol Oncol 98:141-5. 2005
  8. ncbi request reprint In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines
    Judith A Smith
    Department of Gynecologic Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, P O Box 301439 UNIT 1362, Houston, TX 77230 1439, USA
    Cancer Chemother Pharmacol 62:51-8. 2008
  9. pmc Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial
    Jubilee Brown
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4973-9. 2010
  10. doi request reprint In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines
    Anjali Gaikwad
    Department of Gynecologic Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    J Oncol Pharm Pract 15:35-44. 2009

Collaborators

Detail Information

Publications38

  1. ncbi request reprint In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines
    Marisa A Navo
    Division of Pharmacy, The University of Texas, M D Anderson Cancer Center, Houston, TX 77230, USA
    Cancer Chemother Pharmacol 62:483-9. 2008
    ..To determine the growth inhibitory effects of mifepristone on endometrial cancer cell growth and evaluate its effect on apoptosis using HEC-1-A and Ishikawa human endometrial cancer cell lines...
  2. ncbi request reprint Use of complementary and alternative medications among patients in an obstetrics and gynecology clinic
    Judith A Smith
    Division of Surgery, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Reprod Med 57:390-6. 2012
    ..To evaluate the current use of complementary and alternative medication (CAM) products among women in obstetrics and gynecology outpatient clinics...
  3. ncbi request reprint Implementation of cytokines to optimize cancer treatment outcomes
    Judith A Smith
    Department of Gynecologic Oncology, Division of Surgery, The University of Texas M D Anderson Cancer Center, PO Box 301439 Unit 1362, Houston, TX 77230 1439, USA
    J Support Oncol 5:89-91. 2007
  4. ncbi request reprint An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines
    Judith A Smith
    Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Gynecol Oncol 92:314-9. 2004
    ..To determine the cytotoxic activity of gemcitabine on a panel of endometrial cancer cell lines and to determine if the addition of platinum agents enhanced this activity...
  5. ncbi request reprint Evaluation of patient chemotherapy education in a gynecology oncology center
    Judith A Smith
    Division of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Support Care Cancer 12:577-83. 2004
    ..To assess the level at which patient chemotherapy education needs are being met by the health-care team in an outpatient clinic setting and to identify any unmet needs regarding patient chemotherapy education...
  6. ncbi request reprint Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines
    Judith A Smith
    Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Gynecol Oncol 103:518-22. 2006
    ..To evaluate the mechanism that gemcitabine modulates cisplatin drug resistance in endometrial cancer cell lines...
  7. ncbi request reprint An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines
    Judith A Smith
    Department of Gynecologic Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Gynecol Oncol 98:141-5. 2005
    ..The objectives of this study were to determine the optimum schedule for combination of taxane and platinum agents in human ovarian carcinoma cell lines...
  8. ncbi request reprint In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines
    Judith A Smith
    Department of Gynecologic Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, P O Box 301439 UNIT 1362, Houston, TX 77230 1439, USA
    Cancer Chemother Pharmacol 62:51-8. 2008
    ..In addition, the effect of gefitinib on the expression of ATP-binding cassette (ABC) transport proteins was evaluated...
  9. pmc Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial
    Jubilee Brown
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4973-9. 2010
    ..Because the combination of gemcitabine and cisplatin demonstrated synergism in preclinical studies, the authors attempted to determine the efficacy and toxicity of this combination in women with advanced or recurrent endometrial cancer...
  10. doi request reprint In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines
    Anjali Gaikwad
    Department of Gynecologic Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    J Oncol Pharm Pract 15:35-44. 2009
    ..In addition, the effect of gefitinib on the expression of ATP-binding cassette (ABC) transport proteins was evaluated...
  11. doi request reprint Comparison of chemotherapy education and patient preferences in community versus academic gynecology oncology clinics
    Kellie L Jones
    Division of Pharmacy, The University of Texas, M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Oncol Pharm Pract 14:31-6. 2008
    ..To evaluate and compare patients' preferences in receiving chemotherapy education from health care teams in community versus academic clinics...
  12. pmc Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer
    Justin M Julius
    Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Int J Gynecol Cancer 23:348-54. 2013
    ....
  13. ncbi request reprint Evaluation of liposomal curcumin cytochrome p450 metabolism
    Claire M Mach
    Department of Gynecologic Oncology, Division of Surgery, P O Box 301439 UNIT 1362, Houston, Texas 77230 1439, USA
    Anticancer Res 30:811-4. 2010
    ..The objective of this study was to characterize the hepatic metabolism of synthetic curcumin used in the liposomal curcumin formulation...
  14. doi request reprint Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum
    Pedro T Ramirez
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Gynecol Oncol 110:56-9. 2008
    ..To evaluate the efficacy and safety of letrozole in patients with recurrent platinum- and taxane-resistant estrogen receptor-positive (ER+) high-grade cancer of the ovary or peritoneum...
  15. ncbi request reprint Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model
    Jenifer M Saucier
    Department of Gynecologic Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Oncol Pharm Pract 13:39-45. 2007
    ....
  16. doi request reprint Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer
    Janos L Tanyi
    Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas 77230 1439, USA
    Gynecol Oncol 114:219-24. 2009
    ..We sought to characterize the efficacy and adverse-effect profile of PLD in different doses and to evaluate predictive factors of palmar-plantar erythrodysesthesia (PPE)...
  17. doi request reprint Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma
    Lois M Ramondetta
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas
    Cancer 115:1867-74. 2009
    ..The objective of this study was to determine the efficacy of mifepristone (RU-486) in women with advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma (LGESS)...
  18. doi request reprint Defining the role of echinocandin catechol functional groups in the development of secondary hepatocellular carcinoma
    Justin M Julius
    Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Antimicrob Chemother 67:422-9. 2012
    ....
  19. ncbi request reprint Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients
    Marisa Navo
    Division of Pharmacy, The University of Texas, MD Anderson Cancer Center UTMDACC, Houston, TX 77230 1439, USA
    Gynecol Oncol 103:608-13. 2006
    ....
  20. doi request reprint Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA)
    Rodney J Hunter
    Division of Pharmacy, The University of Texas, M D Anderson Cancer Center, Houston, TX 77230, USA
    Cancer Treat Rev 35:69-78. 2009
    ..Under dosing patients with treatable or even curable disease to prevent toxicities could be costing the obese oncology patient population months to years of overall survival...
  21. ncbi request reprint Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model
    Claire M Mach
    Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, U S A
    Anticancer Res 29:1895-9. 2009
    ..This study was designed to determine the minimum effective dose (MED) as well as the optimal dosing schedule of liposomal curcumin in a xenograft mouse model of human pancreatic cancer...
  22. doi request reprint Evaluation of the maternal-fetal transfer of granisetron in an ex vivo placenta perfusion model
    Justin M Julius
    Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
    Reprod Toxicol 49:43-7. 2014
    ..However, there consistently was no detectable passage in all the placentas evaluated of the granisetron at 5ng/mL concentration that would be achieved after transdermal patch administration. ..
  23. doi request reprint Utilization of an ex vivo human placental perfusion model to predict potential fetal exposure to carboplatin during pregnancy
    Judith A Smith
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Texas Health University of Texas Medical School at Houston, Houston, TX Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX Division of Pharmacy, University of Texas M D Anderson Cancer Center, Houston, TX Electronic address
    Am J Obstet Gynecol 210:275.e1-9. 2014
    ..The objective of this study was to determine the fetal drug compartment concentrations when various concentrations of carboplatin cross the placental-trophoblastic barrier and the effect on the fetal kidneys...
  24. ncbi request reprint Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer
    Charlotte C Sun
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Unit 440, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA
    Support Care Cancer 13:219-27. 2005
    ..Selection of second- or third-line chemotherapy ultimately depends on patient preferences for different side effects. To better understand this process, we evaluated preferences and symptom distress in patients with ovarian cancer...
  25. ncbi request reprint Defining the impact of the use of granulocyte colony stimulating factors on the incidence of chemotherapy-induced neutropenia in patients with gynecologic malignancies
    Justin M Julius
    Division of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Oncol Pharm Pract . 2015
    ....
  26. doi request reprint Evaluating the potential effect on fetal tissue after exposure to granisetron during pregnancy
    Judith A Smith
    Department of Gynecology, Obstetrics and Reproductive Sciences, UT Health University of Texas Medical School at Houston, Houston, TX, United States Electronic address
    Reprod Toxicol 53:92-8. 2015
    ..At granisetron 3 ng/mL there was no detectable toxicity or on any fetal tissue in this study. Further research is needed to confirm these preliminary findings and determine if clinically significant...
  27. ncbi request reprint Treatment options for nausea and vomiting during pregnancy
    Martina L Badell
    Department of Obstetrics, Gynecology and Reproductive Sciences, University of Texas Health Science Center at Houston Medical School, Houston, Texas 77230 1439, USA
    Pharmacotherapy 26:1273-87. 2006
    ..Given the substantial health care costs, as well as indirect costs, and the potential decrease in quality of life due to NVP, providers need to acknowledge the impact of NVP and provide appropriate treatment...
  28. doi request reprint Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model
    Judith A Smith
    Department of Gynecology, Obstetrics and Reproductive Sciences, University of Texas Health Science Center Medical School at Houston, 6431 Fannin Street, Houston, TX 77030, USA Department of Pharmacy, UTHealth Memorial Hermann Hospital Cancer Center, 6400 Fannin Street, Suite 2900, Houston, TX 77030, USA Electronic address
    Gynecol Oncol 141:357-63. 2016
    ..The objective of this study was to evaluate the in vivo growth inhibition activity and tumor distribution of Doxil® compared to Lipodox® as its generic (GLD) in human ovarian cancer orthotopic mouse model...
  29. ncbi request reprint An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies
    Marisa A Navo
    College of Pharmacy, University of Houston, TX, USA
    J Clin Oncol 22:671-7. 2004
    ..To describe and assess the current utilization of complementary and alternative medicines (CAMs) in women with a diagnosis of either gynecologic or breast cancer and evaluate their reasons for use...
  30. ncbi request reprint In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin
    Dawn E Colburn
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Hematology 9:217-21. 2004
    ..Azole antifungal agents are increasingly used in this context. In vitro assays were performed to assess whether cytochrome P450 (CYP450) enzymes were affected by combinations of cytarabine or idarubicin with itraconazole or caspofungin...
  31. doi request reprint Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment
    Judith A Smith
    Department of Obstetrics, Gynecology and Reproductive Sciences, UTHealth Medical School, Houston, TX, USA
    J Oncol Pharm Pract 22:599-604. 2016
    ..The objective was to compare toxicity and clinical activity of Lipodox® with Doxil®...
  32. doi request reprint Evaluation of intervention to prevent hypomagnesemia in cervical cancer patients receiving combination cisplatin and radiation treatment
    Rodney J Hunter
    Division of Pharmacy, The University of Texas M D Anderson Cancer Center, CPB6 3244, 1155 Herman Pressler, Unit 1362, Houston, TX 77230, USA
    Support Care Cancer 17:1195-201. 2009
    ....
  33. ncbi request reprint Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development
    Judith A Smith
    Division of Pharmacy, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 90, Houston, TX 77030, USA
    J Clin Pharmacol 43:1008-14. 2003
    ..Future karenitecin clinical trials should include studies to monitor or evaluate the effects of these potential drug interactions on the overall toxicity of karenitecin when used in combination with other drugs...
  34. ncbi request reprint Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy
    Abigail L Sommer
    Division of Pharmacy, The University of Texas, MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Oncol Pharm Pract 12:143-54. 2006
    ..To provide oncology healthcare providers with information on current vaccine recommendations and discuss the proper timing of vaccination in relation to chemotherapy, to allow for an adequate, protective antibody response...
  35. doi request reprint Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer
    Justin M Julius
    Division of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Pharmacotherapy 31:280-97. 2011
    ..Whereas the introduction of the HPV vaccine was an enormous advancement in the cancer prevention research arena, optimization of its clinical use is still needed...
  36. ncbi request reprint Biologic agents for the treatment of juvenile rheumatoid arthritis: current status
    Ruy Carrasco
    Levinson Chair of Pediatric Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Paediatr Drugs 6:137-46. 2004
    ..Randomized trials are ongoing to better define both the efficacy and safety of these novel treatments for children with JRA and other rheumatic diseases...
  37. pmc Endoplasmic reticulum stress and the unfolded protein response are linked to synergistic IFN-beta induction via X-box binding protein 1
    Judith A Smith
    William S Rowe Division of Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229 3039, USA
    Eur J Immunol 38:1194-203. 2008
    ....
  38. pmc The angiotensin-converting enzyme (ACE) gene family of Anopheles gambiae
    Susan Burnham
    Faculty of Biological Sciences, Miall Building, University of Leeds, Clarendon Way, Leeds LS2 9JT, UK
    BMC Genomics 6:172. 2005
    ..Sequencing of the A. gambiae genome has revealed a number of ACE-like genes but probable errors in the Ensembl annotation have left the number of ACE-like genes, and their structure, unclear...